

Cause-specific excess mortality among dialysis patients: A comparison with the general population in Japan.

Authors' full names:

Minako Wakasugi*, Junichiro James Kazama‡, Suguru Yamamoto†, Kazuko Kawamura†, Ichiei Narita†.

Affiliations:

*Center for Inter-organ Communication Research, Niigata University Graduate School of Medical and Dental Sciences, †Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, and ‡Division of Blood Purification Therapy, Niigata University Medical and Dental Hospital

Corresponding author:

Minako Wakasugi, M.D., M.P.H., PhD.

Asahimachi 1-757, Chuo-ku, Niigata 951-8510, Japan

Phone: +81-25-227- 2116

FAX: +81-25-227-2116

E-mail: minakowa@med.niigata-u.ac.jp

Running title: Cause-specific Excess Mortality and Dialysis

Abstract

Background

Despite significant therapeutic advances, mortality of dialysis patients remains unacceptably high. The aim of this study is to compare mortality and its causes in dialysis patients with those in the general Japanese population.

Methods

We used data for 2008 and 2009 from the Japanese Society for Dialysis Therapy registry and a national Vital Statistics survey. Cardiovascular mortality was defined as death attributed to heart failure, cerebrovascular disorders, myocardial infarction, hyperkalemia/sudden death, and pulmonary thromboembolism. Non-cardiovascular mortality was defined as death attributed to infection, malignancies, cachexia/uremia, chronic hepatitis/cirrhosis, ileus, bleeding, suicide/refusal of treatment, and miscellaneous. We calculated standardized mortality ratios and age-adjusted mortality differences between dialysis patients and the general population for all-cause, cardiovascular *versus* non-cardiovascular, and cause-specific mortality.

Results

During the two-year study period, there were 2 284 272 and 51 432 deaths out of 126 million people and 273 237 dialysis patients, respectively. The standardized mortality ratio for all-cause mortality was 4.6 (95% confidence interval, 4.6-4.7) for the dialysis patients compared to the general population. Age-adjusted mortality differences for cardiovascular and non-cardiovascular disease were 33.1 and 30.0 per 1 000 person-years, respectively. The standardized mortality rate ratios were significant for all cause-specific mortality rates except accidental death.

Conclusions

Our study revealed that excess mortality in dialysis patients compared to the general population in Japan is large, and differs according to age and cause of death. Cause-specific mortality studies should be planned to improve life expectancies of dialysis patients.

Key Words: dialysis, general population, excess mortality, standardized mortality ratio

Introduction

According to the Japanese Society for Dialysis Therapy (JSDT) registry, more than 25 000 dialysis patients die every year in Japan (1). Despite significant therapeutic advances, the annual crude mortality rate of dialysis patients has been approximately 9.5% since 1992, and was 9.8% in 2008 (1). The life expectancy of dialysis patients was approximately half that of the general population of the same sex and age, in all age ranges (2). These findings suggest that there is still significant room for improvement in life prognosis for dialysis patients.

Evidence is accumulating that excess mortality in dialysis patients can be explained by both cardiovascular and non-cardiovascular causes (3,4). For example, European incident dialysis patients have 8.8- and 8.1-fold higher cardiovascular and non-cardiovascular mortality, respectively, than the general population (4). However, little is known about excess mortality of Japanese dialysis patients. In Japan, life expectancy at birth is now the longest in the world (5), and the incidence of cardiovascular disease is relatively low compared to the United States and Europe (6). To improve the prognosis of Japanese dialysis patients, it is necessary to determine the cardiovascular and non-cardiovascular mortality rates of dialysis patients compared to the Japanese general population. It is also necessary to determine cause-specific mortality rates because excess mortality will differ among causes of death.

The aim of this study is to compare mortality and its causes in dialysis patients with those in the general Japanese population.

Materials and Methods

Data sources

We extracted mortality data of dialysis patients from the annual data reported by the JSDT Renal Data Registry Committee for 2008 and 2009, which included a total of 51 423 deaths (7,8). The details of the JSDT registry data collection techniques and the characteristics of this dialysis population have been described elsewhere (1). The JSDT registry collects data on medical history, treatment conditions, and outcomes of individual dialysis patients from dialysis facilities in Japan every year by questionnaire.

We obtained mortality data for the general population from a national survey. The National Vital Statistics Survey Form consists of five forms: Live Birth Form, Death Form, Fetal Death Form, Marriage Form, and Divorce Form. We used data from the Death Form, which is based on Notification of Death, and included a total of 2.28 million deaths for 2008 and 2009 (9,10).

Case definitions

Causes of death for both the dialysis patients and general population were followed by the JSDT definition using the 10th modified edition of the International Classification of Diseases (ICD-10) codes (11) (**Appendix**). It is important to note that our analyses included the annual mortality due to a certain disease rather than the fatality rate, which is the ratio of deaths among patients presenting with a certain disease over a certain period of time.

Data analysis

We analyzed all-cause mortality first, then estimated cardiovascular and non-cardiovascular mortality, and finally calculated cause-specific mortality. We defined cardiovascular mortality as deaths attributed to heart failure, cerebrovascular disorder, myocardial infarction, hyperkalemia/sudden death, and pulmonary thromboembolism. We defined non-cardiovascular mortality as deaths from all other causes, i.e., infection, malignancies, cachexia/uremia, chronic hepatitis/cirrhosis, ileus, bleeding, suicide/refusal of treatment, and miscellaneous. Accidental deaths and deaths with unknown causes were excluded from analysis.

The calculation methods have been described previously in detail (12). Briefly, we categorized both the dialysis patients and the general population into five age groups: 0–29, 30–44, 45–59, 60–74, and ≥ 75 years. Mortality rates were calculated by dividing the number of deaths by the number of person-years accumulated during the study period. We estimated the number of person-years during the study period as twice the population at the mid-point (13). We calculated the expected number of deaths by multiplying the total number of person-years during the study period by the corresponding age-specific mortality rate for the general population. Standardized mortality ratios (SMRs) were then calculated as the ratio between the observed and expected number of deaths. We calculated confidence intervals (CIs) for the SMRs using the normal approximation of the Poisson distribution. The SMR can be interpreted as the relative difference in the mortality rate among the dialysis patients compared with that of the general population. We calculated the age-adjusted mortality rate difference to determine whether there was excess mortality in dialysis patients compared with the general population on an absolute scale. We also calculated the percent difference in all-cause mortality to determine the

contributions of cause-specific mortality to any differences observed in all-cause mortality (14).

Results

During the two-year study period, there were 2 284 272 and 51 423 deaths recorded out of 126 million people and 273 237 dialysis patients, respectively. The crude all-cause mortality rate was 9.06 and 94.10 per 1 000 person years in the general population and the dialysis population, respectively (Table 1). The SMR for all-cause mortality was 4.6 (95% CI: 4.6 - 4.7) for the dialysis patients with respect to the general population.

The proportions of cardiovascular and non-cardiovascular mortality in dialysis patients were approximately 46% (21 155 of 45 847 known causes of death) and 53% (24 351 of 45 847 known causes of death), respectively. The SMRs for cardiovascular and non-cardiovascular diseases were 6.7 (95% CI: 6.9-7.1) and 3.1 (95% CI: 3.0-3.1) times higher in dialysis patients than in the general population. The age-adjusted mortality rate difference for cardiovascular diseases (33.1 per 1 000 person-years) was similar to that for non-cardiovascular diseases (30.0 per 1 000 person-years).

SMRs for cause-specific mortality were significantly higher for hyperkalemia/sudden death, bleeding, heart failure, pulmonary thromboembolism, chronic hepatitis/cirrhosis, infectious disease, cachexia/uremia, ileus, cerebrovascular disorder, suicide/refusal of treatment, myocardial infarction, miscellaneous (ICD-10 codes in Appendix), and malignancies, in descending order. Figure 1 shows cause-specific mortality among dialysis patients compared with the general population.

Mortality rates were higher in the elderly than in young individuals. Notably, mortality rates for hyperkalemia/sudden death were higher even among younger dialysis patients. While other cause-specific mortality rates increased exponentially with age, the mortality rates of suicide/refusal of treatment almost plateaued between the ages of 45 and 74 in both the dialysis patients and general population. The mortality rates of chronic hepatitis/cirrhosis increased with age until 74 years old, and then slightly decreased. The mortality rate of accidental death was similar between the dialysis patients and the general population. Values in Figure 1 reflect mortality rates in dialysis patients compared with the general population in the 60-74-year-old group, since most dialysis patients in Japan belong to this age group. Mortality rates associated with hyperkalemia/sudden death and heart failure were markedly higher in dialysis patients compared with the general population, being 46- and 36-fold higher, respectively, in the 60-74-year-old group.

Discussion

The present study showed that all-cause mortality among Japanese dialysis patients was approximately five-fold higher than in the general population. We also showed that the age-adjusted mortality rate difference for cardiovascular diseases was similar to that for non-cardiovascular diseases. These findings indicate that preventing both cardiovascular and non-cardiovascular deaths is important for decreasing all-cause mortality among Japanese dialysis patients. We also revealed that excess mortality in dialysis patients differed with cause of death. These results indicate that countermeasures against each cause of death are needed to improve prognosis of dialysis patients.

Several characteristic findings of the cause-specific excess death should be discussed. Mortality due to hyperkalemia/sudden death was extremely high among dialysis patients compared to the general population, even among younger dialysis patients. This suggests that we should place a high priority on preventing these deaths, especially among young patients. However, the diagnosis of hyperkalemia is not completely reliable. Postmortem examination of 35 sudden death cases in chronic dialysis patients showed that dissecting aortic aneurysm was the most common cause of sudden death, followed by cerebral hemorrhage, acute subdural hematoma, acute myocardial infarction, cerebral infarction, and subarachnoid hemorrhage (15). Thus, some cases of sudden death might be due to cardiovascular diseases rather than hyperkalemia. Further detailed study is needed to prevent sudden death among dialysis patients, especially among younger dialysis patients.

In this study, dialysis patients had a 190% higher rate of suicide/refusal of treatment than the general population. This rate is unacceptably high given that the suicide rate in the Japanese general population is the eighth highest in the world and the highest among developed countries (16). Published information regarding suicide in dialysis patients is scarce. Patients with end-stage renal disease have an 84% higher rate of suicide compared with the general population in the United States (17). Our study did not distinguish between suicide and refusal of treatment, but the suicide rate in the Japanese dialysis population might be high because untreated depression is the leading cause of suicide among the general population, and dialysis patients with depression have been underdiagnosed and undertreated in Japan (18). This issue also requires further detailed investigation.

We found that mortality rates of chronic hepatitis/cirrhosis slightly decreased after age 75, while other cause-specific mortality rates increased after age 75. There are several possible explanations for this observation. First, patients with chronic hepatitis/cirrhosis might rarely survive after age 75. This speculation is consistent with the finding that hepatitis C virus (HCV) infection is the most common cause of chronic liver disease in dialysis patients, and anti-HCV-positive patients on dialysis have an increased risk of mortality compared with anti-HCV-negative patients (19). Second, patients with chronic hepatitis/cirrhosis over age 75 might die from other causes, because dialysis patients have many competing mortality risks. A prospective cohort study showed that cardiovascular disease, cerebrovascular disease, infection, and cancer account for 65% of the mortality among anti-HCV-positive patients (20). Third, the mortality rate of chronic hepatitis/cirrhosis might decrease because prevalence of the anti-HCV antibody decreases after age 75 (2). Fourth, patients over age 75 might not have a rapidly progressive course of liver cirrhosis. However, it remains controversial whether dialysis patients have a rapid progression to liver cirrhosis compared with the general population (21). Further detailed studies that focus on chronic hepatitis should be planned.

Mortality due to accidental death was similar between dialysis patients and the general population in this study. Japan experiences many different natural disasters, such as earthquakes, tsunamis, and floods. For example, the Iwate-Miyagi Nairiku Earthquake in July 2008, the heavy rainfall disasters in August 2008, the Chugoku-Kyushu-Hokubu Heavy Rainfall in July 2009, and the Shizuoka Earthquake in August 2009 occurred during the study period. These findings suggest that Japanese disaster relief activity would protect dialysis patients against mortality from these natural disasters. In fact,

when the Great East Japan Earthquake occurred on March 11, 2011, many physicians and networks in Japan worked together to successfully transfer many dialysis patients (22,23). However, since our study period had a relatively little human suffering caused by the natural disasters, we must reevaluate this issue.

The study had some limitations that should be noted. First, we could not separate deaths among dialysis patients from the national data that we used as a reference group. However, the magnitude of this problem is negligible because these deaths represent <3% of all national deaths. Second, we only adjusted the SMRs for age. We lacked sufficient data to evaluate the number of patients stratified by gender, dialysis vintage, or dialysis modality. Life expectancies are higher for females than for males in the general population. Similarly, life expectancies are higher for females than for males in all age ranges of the dialysis population (2). More precise analysis is needed. Finally, we could not confirm the validity of diagnoses listed as cause of death. In addition, there was a large proportion of “Unknown” causes of death among the dialysis patients. Some studies have reported that death certificates and registry reports provide differing causes of death for patients with end-stage renal disease (24,25). Concordance assessment is needed in Japan to develop a clear epidemiological picture among dialysis patients.

Despite these limitations, this study has several strengths. Our study used data from a national Vital Statistics survey and a nationwide survey of Japanese dialysis facilities. Both surveys are an almost complete national census. In addition, we comprehensively evaluated cause-specific excess mortality among Japanese dialysis patients compared to the general population. In addition, as far as we know, this is the first report about the risk of accidental death among dialysis patients in comparison with

the general population. Finally, our findings provide valuable data on unresolved issues concerning cause-specific excess mortality among Japanese dialysis patients.

Conclusions

Our study revealed that excess mortality in dialysis patients compared to the general population in Japan is large, and differs according to age and cause of death. Cause-specific mortality studies should be planned to improve life expectancies of dialysis patients.

Acknowledgement

We thank the Committee of the Renal Data Registry of the Japanese Society for Dialysis Therapy (JSDT) for permission to use the data. The opinions reflected in this manuscript are those of the authors alone and do not reflect an official position of JSDT. None of the authors have any conflicts of interest associated with this study.

References

1. Nakai S, Suzuki K, Masakane I et al. An overview of regular dialysis treatment in Japan (As of 31 December 2008). *Ther Apher Dial* 2010;14:505-40.
2. Nakai S, Masakane I, Akiba T et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). *Ther Apher Dial* 2007;11:411-41.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;32(suppl 3):S112-9.
4. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. *JAMA* 2009;302:1782-9.
5. World Health Organization. World Health Statistics 2009. Geneva: World Health Organization; 2009.
6. Yoshino M, Kuhlmann MK, Kotanko P et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. *J Am Soc Nephrol* 2006;17:3510-9.
7. Patient Registration Committee. In: Tsubakihara Y, ed. *An overview of regular dialysis treatment in Japan as of Dec. 31, 2009 CD-ROM*. Tokyo, Japan: Japanese Society for Dialysis Therapy; 2010. Tables 123 and 2676.
8. Patient Registration Committee. In: Tsubakihara Y, ed. *An overview of regular dialysis treatment in Japan as of Dec. 31, 2008 CD-ROM*. Tokyo, Japan: Japanese Society for Dialysis Therapy; 2009. Tables 115 and 102.
9. Bureau of Census, Ministry of Internal Affairs and Communications. http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&listID=000001057801&disp=Other&requestSender=dsearch (Accessed July 23, 2011)

10. Bureau of Census, Ministry of Internal Affairs and Communications. http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&listID=000001066499&disp=Other&requestSender=dsearch (Accessed July 23, 2011)
11. Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan. An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003. *Ther Apher Dial* 2005;9:431-58.
12. Wakasugi M, Kawamura K, Yamamoto S et al. High mortality rate of infectious diseases among dialysis patients: A comparison with the general population in Japan. *Ther Apher Dial* (in press).
13. Esteve J, Benhamou E, Raymond L. Techniques for the analysis of Cancer Risk. In: Esteve J, Benhamou E, Raymond L, eds. *Statistical Methods In Cancer Research: Volume IV: Descriptive Epidemiology*. Lyon, France: International Agency for Research on Cancer; 1994; 49-105.
14. Richardus JH, Kunst AE. Black-white differences in infectious disease mortality in the United States. *Am J Public Health*. 2001;91:1251-3.
15. Takeda K, Harada A, Okuda S et al. Sudden death in chronic dialysis patients. *Nephrol Dial Transplant* 1997;12:952-5.
16. World Health Organization: SUPRE. http://www.who.int/mental_health/prevention/suicide/supresuicideprevent/en/ (Accessed 1, June, 2009)
17. Kurella M, Kimmel PL, Young BS et al. Suicide in the United States end-stage renal disease program. *J Am Soc Nephrol* 16:774-781, 2005.

18. Fukuhara S, Green J, Albert J et al. Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. *Kidney Int* 2006;70:1866-72.
19. Fabrizi F, Takkouche B, Lunghi G et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. *J Viral Hepat* 2007;14:697-703.
20. Nakayama E, Akiba T, Marumo F et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. *J Am Soc Nephrol* 2000;11:1896-902.
21. Espinosa M, Martin-Malo A, Alvarez de Lara MA et al. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. *Nephrol Dial Transplant* 2001;16:1669-74.
22. Nangaku M, Akizawa T. Diary of a Japanese nephrologist during the present disaster. *Kidney Int* 2011;79:1037-9.
23. Kazama JJ, Narita I. Earthquake in Japan. *Lancet* 2011;377:1652-3.
24. Perneger TV, Klag MJ, Whelton PK. Cause of death in patients with end-stage renal disease: death certificates vs registry reports. *Am J Public Health* 1993;83:1735-8.
25. Li SQ, Cass A, Cunningham J. Cause of death in patients with end-stage renal disease: assessing concordance of death certificates with registry reports. *Aust N Z J Public Health* 2003;27:419-24.